Company Profile
Zentalis Stock Price, News & Analysis
- Ticker:
- ZNTL
- Exchange:
- NASDAQ
- Sector:
- Small Molecule Drugs
- Location:
- United States
Stock performance
5.00 USD (+1.01%)
Close
Last updated: August 6, 2026
281M USD
Market cap
Why the stock is moving
The latest monitored company update is “Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates.” The corresponding closing-price reaction is not yet available.
Company overview
Cell-Cycle Oncology Company
Zentalis Pharmaceuticals develops azenosertib, an oral inhibitor of WEE1, a regulator of DNA-damage checkpoints and cell-cycle progression.
Cyclin E1-Positive Ovarian Cancer
The lead program targets platinum-resistant ovarian cancers with Cyclin E1 expression, where replication stress may create heightened dependence on WEE1.
DENALI and ASPENOVA
DENALI is the registration-intended Phase 2 monotherapy study, while ASPENOVA is a Phase 3 confirmatory trial intended to support full approval and ex-U.S. registrations.
Future catalysts
Topline results from the Phase 2 DENALI study are expected by year-end 2026 and may support an Accelerated Approval pathway, subject to the data and FDA feedback.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Zentalis (ZNTL)?
Zentalis (ZNTL) most recently closed at 5.00 USD, a +1.01% move versus the previous session.
What is the market cap of Zentalis (ZNTL)?
Zentalis currently has a market capitalization of 281M USD on BioPharmSignal.
What does Zentalis do?
Cell-Cycle Oncology Company Zentalis Pharmaceuticals develops azenosertib, an oral inhibitor of WEE1, a regulator of DNA-damage checkpoints and cell-cycle progression. Cyclin E1-Positive Ovarian Cancer The lead program targets platinum-resistant ovarian cancers with Cyclin E1 expression, where replication stress may create heightened dependence on...
On which exchange is ZNTL stock listed?
Zentalis (ZNTL) is associated with NASDAQ, United States, Small Molecule Drugs.
What is azenosertib?
Cell-Cycle Oncology Company Zentalis Pharmaceuticals develops azenosertib, an oral inhibitor of WEE1, a regulator of DNA-damage checkpoints and cell-cycle progression.
Which conditions is Zentalis targeting with azenosertib?
Zentalis is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Zentalis describe recent progress with azenosertib?
Topline results from the Phase 2 DENALI study are expected by year-end 2026 and may support an Accelerated Approval pathway, subject to the data and FDA feedback.
What is Cell-Cycle?
Cell-Cycle Oncology Company Zentalis Pharmaceuticals develops azenosertib, an oral inhibitor of WEE1, a regulator of DNA-damage checkpoints and cell-cycle progression.